Precipio, Inc. (PRPO)
| Market Cap | 48.18M +346.1% |
| Revenue (ttm) | 22.80M +31.0% |
| Net Income | -1.25M |
| EPS | -0.82 |
| Shares Out | 1.75M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,382 |
| Open | 27.01 |
| Previous Close | 26.93 |
| Day's Range | 27.00 - 27.50 |
| 52-Week Range | 3.90 - 29.53 |
| Beta | 1.25 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Apr 2, 2026 |
About PRPO
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.
Financial Performance
In 2024, Precipio's revenue was $18.53 million, an increase of 21.95% compared to the previous year's $15.20 million. Losses were -$4.29 million, -26.70% less than in 2023.
Financial StatementsNews
Precipio Announces Q4 and year-end 2025 Shareholder Update Call
NEW HAVEN, Conn., March 12, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q4 and year end 2025 corporate update call on April 2nd, 20...
Precipio 2025 (Unaudited) Revenues Grew to $24.0M, a 30% Increase Year-Over-Year
In Q4-2025 the Company generated ~$400K in Operating Cash Flow, and Adjusted EBITDA of close to $1M In Q4-2025 the Company generated ~$400K in Operating Cash Flow, and Adjusted EBITDA of close to $1M
Precipio Takes Major Steps Toward a Clean Balance Sheet
Less than $80,000 of long-term debt, and 10,000 vendor warrants remain outstanding Less than $80,000 of long-term debt, and 10,000 vendor warrants remain outstanding
Precipio to Showcase its BCR::ABL1 panel at 2025 ASH (American Society of Hematology) Meeting
Joint study conducted with Memorial Sloan Kettering Cancer Center demonstrates clear, positive impacts on patient care Joint study conducted with Memorial Sloan Kettering Cancer Center demonstrates cl...
Precipio Identifies Unauthorized Access to Isolated Storage; No Operational Impact
NEW HAVEN, Conn., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Precipio, Inc. reports that the Company recently identified a single, limited scope unauthorized access to a specific data folder stored within its ...
Precipio Announces its Q3-2025 Financial Results
Over $450,000 Adjusted EBITDA and $275,000 positive operating cash flow for the quarter Over $450,000 Adjusted EBITDA and $275,000 positive operating cash flow for the quarter
Precipio Announces Q3-2025 Shareholder Update Call
NEW HAVEN, Conn., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q3-2025 corporate update call on November 17th, 2025 at 5:00...
Precipio Announces its Q2-2025 Financial Results
NEW HAVEN, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , filed its 10-Q report today.
Precipio Announces Q2-2025 Shareholder Update Call
NEW HAVEN, Conn., July 31, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q2-2025 corporate update call on August 14th, 2025 at 5:00 P...
Precipio Enters Into Agreement With Warrant Holder To Exercise Majority Of Warrants As Cashless
NEW HAVEN, Conn., July 11, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) has entered into an agreement with its largest warrant holder, amending the ex...
Precipio Announces its Q1-2025 Financial Results
NEW HAVEN, Conn., May 14, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , filed its 10-Q report today.
Precipio Announces Q1-2025 Shareholder Update Call
NEW HAVEN, Conn., May 01, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its Q1-2025 corporate update call on May 15th, 2025 at 5:00 P...
Precipio Announces Q4 and year-end 2024 Shareholder Update Call
NEW HAVEN, Conn., March 17, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q4 and year end 2024 corporate update call on March 31st, 2...
Precipio Achieves Key Q4-2024 Financial Goals: Positive Adjusted EBITDA and Positive Cash Flow (unaudited)
Both metrics demonstrate the ability to achieve financial independence Both metrics demonstrate the ability to achieve financial independence
Precipio grants senior management performance-based awards instead of traditional time-vested ESOPs
NEW HAVEN, Conn., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announced that options granted to senior management on January 14 would vest...
Precipio Announces Q3-2024 Shareholder Update Call
NEW HAVEN, Conn., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q3-2024 corporate update call on November 18th at 5:00 PM ET...
Precipio Expands Bloodhound™ MPN Panel by Adding CALR Mutation Subtyping
The unique assay enables laboratories to provide clinicians with more informed treatment decisions for their patients The unique assay enables laboratories to provide clinicians with more informed tre...
Precipio Announces Employee Stock Option Plan Repricing
NEW HAVEN, Conn., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the Company's repricing of a portion of its employee stock options ...
Precipio Announces Q2-2024 Shareholder Update Call
NEW HAVEN, Conn., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its Q2-2024 corporate update call on August 19th at 5:00 PM ...
Precipio Reports $0.3M cash generated by operations (unaudited) in Q2-2024, as the company advances towards breakeven
Company's continued growth and improved cash position alleviates the need for capital raise in the foreseeable future Company's continued growth and improved cash position alleviates the need for capi...
Precipio Reports $4.4M for Q2-2024 (unaudited) Revenues, a leap of 30% from Q1-2024
Pathology Revenues in June exceed breakeven target and continue growth trend Pathology Revenues in June exceed breakeven target and continue growth trend
Precipio Inc. Announces Adjournment of Annual Meeting of Stockholders
New Shareholders Meeting Date: Friday, June 21 at 9 a.m. Eastern Time New Shareholders Meeting Date: Friday, June 21 at 9 a.m. Eastern Time
Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting
NEW HAVEN, Conn., June 12, 2024 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) is requesting that shareholders instruct their brokers to vote t...
Precipio Secures a short-term $500K Credit Facility
Loan will supplement any temporary cashflow deficit related to cash collections delay due to Change Healthcare cybersecurity attack Loan will supplement any temporary cashflow deficit related to cash ...
Precipio Announces Year end 2023 Shareholder Update Call
NEW HAVEN, Conn., March 25, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its year end 2023 corporate update call on April 1st, 2024 at 5...